《恶性嗜铬细胞瘤的治疗课件_1》由会员分享，可在线阅读，更多相关《恶性嗜铬细胞瘤的治疗课件_1（35页珍藏版）》请在金锄头文库上搜索。
1、Therapy of Malignant Pheochromocytoma 恶性嗜铬细胞瘤的治疗,Literature Report,2018/10/3,2,Introduction,rule of 10s for pheochromocytoma (PCC)10% bilateral10% extra-adrenal10% extra-abdomen10% malignant10% familial10% children10% normal blood pressure,2018/10/3,3,Introduction,The most frequent site of metastase
2、s is the skeleton Additional sites are liver, retroperitoneum with lymph nodes, CNS, pleura, and kidney,2018/10/3,4,Malignant vs. Benign,Currently, there is no effective cure for malignant pheochromocytoma. There are also no reliable histopathological methods for distinguishing benign from malignant
3、 tumors. Malignancy requires evidence of metastases at non-chromaffin sites distant from that of the primary tumor.,2018/10/3,5,Metastatic disease in pheochromocytoma may be present at the time of initial diagnosis or may only became evident after surgical removal of the primary tumor, usually withi
4、n 5 years, but sometimes 16 or more years later.,2018/10/3,6,Due to the rarity of the tumor, clinical studies about pheochromocytoma suffer from a fragmented nature and usually involve too small a number of cases to reach conclusive results.,2018/10/3,7,Because there is currently no effective cure f
5、or malignant pheochromocytoma, most treatment are palliative, but in some cases may reduce tumor burden and prolong survival. Without treatment, the 5-year survival is generally less than 50%. The course, however, can be highly variable with occasional patients living more than 20 years after diagno
6、sis.,2018/10/3,8,Once malignancy is diagnosed, therapy is generally directed at controlling blood pressure, but may also include tumor debulking.,2018/10/3,9,Alternative of Current Therapy,Surgery Radiopharmaceuticals Combined Chemotherapy Arterial Embolization,2018/10/3,10,Alternative of Current Th
7、erapy,Surgery Radiopharmaceuticals Combined Chemotherapy Arterial Embolization,2018/10/3,11,Primary surgical resection is the treatment of choice whenever possible Limited disease: curative intention Extended disease: still to be considered in the first place for debulking and as palliative treatmen
8、t (Mundschenk et al. 1998),2018/10/3,12,Problem,When signs of regional involvement or distant disease are absent, there is currently no reliable preoperative diagnostic test that can differentiate between malignant and benign pheochromocytomas Should pheochromocytoma size influence surgical approach
9、?,2018/10/3,13,A comparison of 90 malignant and 60 benign pheochromocytomas(Wen T. Shen et al.2004) Comparison of tumor size for benign pheochromocytomas and malignant pheochromocytomas with local disease only Size does not reliably predict malignancy in pheochromocytomas with local disease only,201
10、8/10/3,14,2018/10/3,15,Malignant PCCs presenting with only local disease cannot be discriminated from benign PCCs by size alone. When PCCs do not have evidence of invasion or distant metastases and the surgeon acquires an appropriate level of experience, the majority of these tumors can be safely re
11、sected laparoscopically.,2018/10/3,16,Laparoscopic adrenalectomy for pheochromocytoma should be converted to open adrenalectomy for difficult dissection, invasion, adhesions, or surgeon inexperience,2018/10/3,17,Surgical approach,Transabdominal approach is necessary minimally invasive procedures ret
12、roperitoneal approaches should be abandoned to definitely preserve the tumor capsule and perform total lymphadecectomy (Orchard et al. 1993),2018/10/3,18,Secondary Tumors,No experience with adjuvant pre and postoperative radiation exists Generally are multiple Radical surgical resection is often imp
13、ossible Other treatment modalities have to be considered,2018/10/3,19,Alternative of Current Therapy,Surgery Radiopharmaceuticals Combined Chemotherapy Arterial Embolization,2018/10/3,20,2018/10/3,21,131I-MIBG is the treatment of choice for all unresectable, MIBG positive tumors 58 cases of malignan
14、t PCC treated by 131I-MIBGtherapeutic results and adverse events (ZHU Ruisen et al. 1999),2018/10/3,22,Patients were classified into 3 groups according to their tumor size 20 cm3 (26 cases) In group 1, the mean absorption dose per gram of tumor was above 1 000 cGy. After treatment ,tumors disappeare
15、d or shrinked in all patients,2018/10/3,23,In group 2 , the absorption dose was similar to that of group 1, but the mean absorption dose per gram was 717.6 cGy , and tumor mass regression was 36 % ;76 % reduced urinary catecholamine In group 3 , the absorption dose per gram tumor tissue was 277 cGy
16、, and 30 % tumor enlargement , 20 % died ; the remaining 50 % symptomatic improvement without any change in tumor size,2018/10/3,24,131 I-MIBG is of certain therapeutic effectiveness of symptomatic improvement Complete tumor mass disappearance has only been found in small tumors Treatment with 131 I-MIBG should be instituted immediately after surgical resection to eradicate the residual tumor cells and to prevent recurrences Bone marrow suppression is temporary and not dosage related,
